DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain

Information source: Janssen Pharmaceutica
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Moderate to Severe Chronic Non-cancer Pain

Intervention: No intervention (Drug)

Phase: Phase 4

Status: Withdrawn

Sponsored by: Janssen Pharmaceutica

Official(s) and/or principal investigator(s):
Janssen Pharmaceutica Clinical Trial, Study Director, Affiliation: Janssen Pharmaceutica

Summary

The purpose of this study is to evaluate the safety and effectiveness of prolonged release tapentadol hydrochloride for the relief of moderate to severe chronic non-cancer pain among Filipino patients.

Clinical Details

Official title: A Post-Marketing Surveillance (PMS) Study on the Safety and Effectiveness of Prolonged Release Tapentadol Hydrochloride Among Adult Filipino Patients With Moderate To Severe Chronic Non-Cancer Pain

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: Number of patients with incidence of adverse events and adverse drug reactions

Secondary outcome: The short form Brief Pain Inventory (BPI) questionnaire scores

Detailed description: This is an open-label (all people know the identity of the intervention), multi-center (study conducted at multiple sites), observational study (study in which the investigators/ physicians observe the patients and measure their outcomes). The study will enroll approximately 100 patients who will be taking prolonged release tapentadol hydrochloride with a dosing regimen stipulated in the product insert. As this is an observational study, assessment of patient will be based on the accepted clinical practice in the Philippines. Patients will be monitored at baseline (Day 1) and throughout the 84-day treatment period of prolonged release tapentadol hydrochloride (every 7 days for the first two weeks, and thereafter every 28 days for the next three months) for effectiveness with the help of short form Brief Pain Inventory (BPI) questionnaire. Safety evaluations will include assessment of adverse events, clinical laboratory tests, and co-morbid conditions. The total study will be conducted for 3 years and the duration of treatment will be for 84 days.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Filipino patients with moderate to severe non-cancer pain with an onset of 12 weeks

or less from the baseline visit and pain requires Schedule 2 opioid treatment as per assessment of the prescribing physician

- Patients who able to independently communicate pain characteristics, understand and

complete self administered questionnaires

- Medically stable on the basis of routine physical examination, medical history, and

vital signs at the time of baseline visit Exclusion Criteria:

- Refuse to protocol-defined use of effective contraception

- Pregnant and lactating women

- Patients with severe renal and hepatic impairment, significant respiratory

depression, acute or severe bronchial asthma or hypercapnia, and having or suspected paralytic ileus

- Patients with acute intoxication with alcohol, hypnotics, centrally acting

analgesics, or psychotropic drugs or receiving other mu-opioid receptor agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, and sedatives

- Patients who are receiving Monoamine oxidase (MAO) inhibitors or who have taken them

within the last 14 days

- Patients with documented history of increased intracranial pressure, impaired

consciousness, coma and seizure

Locations and Contacts

Additional Information

Starting date: October 2014
Last updated: June 20, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017